Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolytics Biotech ( (ONCY) ) has shared an update.
Oncolytics Biotech Inc. has announced plans to change its jurisdiction of incorporation from Alberta, Canada, to Nevada, USA, through a series of transactions requiring shareholder approval. This move aims to reduce regulatory burdens and costs, facilitate long-term shareholder value creation, and align with the company’s operational focus in the United States, where most of its operations and shareholders are located. The transition is not expected to materially affect the company’s operations or financial results, and its shares will continue to trade on the Nasdaq Capital Market.
The most recent analyst rating on (ONCY) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact.
Average Trading Volume: 1,016,327
Technical Sentiment Signal: Hold
Current Market Cap: $119.5M
Find detailed analytics on ONCY stock on TipRanks’ Stock Analysis page.